Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf ...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...
Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in ...
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results ...
Tezspire hits both primary endpoints in Phase 3 eosinophilic esophagitis trial, addressing histologic remission and dysphagia ...
Generate Biomedicines' GB-0895 Phase 1 data released early, showing results in mild-to-moderate asthma and COPD ahead of ERS ...
Ivonescimab beats durvalumab in Phase III HARMONi-GI1 trial for biliary tract cancer, meeting primary overall survival ...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results